Summary
Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
O'Dwyer PJ, Shoemaker DD, Jayaram HN, Johns DG, Cooney DA, Marsoni S, Malspeis L, Plowman J, Davignon JP, Davis RD: Tiazofurin: a new antitumor agent. Invest New Drugs 2:79–84, 1984
Smejka RM, Page TT, Boyd VL, Nyhan WL, Jacobsen SJ, Mangum JH, Robins RK: Novel nucleoside inhibitors of guanosine metabolism as antitumor agents. Enzyme Regul 22:59–68, 1984
Fridland A, Connelly MC, Robbins TJ: Tiazofurin metaboloism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5′-Nucleotidase. Cancer Res 46:532–537, 1986
Roberts JD, Stewart JA, McCormack JJ, Krakoff IR, Culham CA, Hartshorn JN, Newman RA, Haugh LD, Young JA: Phase I trial of tiazofurin administered by iv bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat Rep 71:141–149, 1987
Melink TJ, Von Hoff DD, Kuhn JG, Hersh MR, Sternson LA, Patton TF, Siegler R, Boldt DH, Clark CM: Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res 45:2859–2865, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holoye, P.Y., Carr, D.T., Dhingra, H.M. et al. Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma. Invest New Drugs 6, 217–218 (1988). https://doi.org/10.1007/BF00175401
Issue Date:
DOI: https://doi.org/10.1007/BF00175401